|Day Low/High||98.45 / 99.33|
|52 Wk Low/High||58.59 / 99.36|
Celgene Corporation (NASDAQ:CELG) today announced the results of a post-hoc analysis of data from the Phase 3 RADIANCE™ Part B trial showing that ozanimod reduced cortical grey matter volume loss versus first-line treatment, Avonex ® (interferon beta-1a),...
Jim Cramer says that although a sell-off can breed a buying opportunity, investors need to worry about sky-high IPOs and other signs of froth.
Nothing’s wrong with a market correction – the Russell 2000 even outperformed – but keep your eyes on the declining McClellan Summation Index.
RMPIA outperformed once gain during April.
Celgene Corporation (Nasdaq: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that the New England Journal of Medicine (NEJM) has published interim results from CRB-401, the ongoing phase 1 study of bb2121, the companies' lead investigational...
Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that Celgene has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for luspatercept for the treatment of adult patients...
Analyzing this year's stock draft contest and individual stock-picking vs. indexing.
Celgene Corporation (NASDAQ:CELG) reported net product sales of $4,024 million for the first quarter of 2019, a 14 percent increase from the same period in 2018.
Bristol-Myers Squibb posted stronger than-expected first quarter earnings Thursday, and boosted one of its key profit forecast, after seeing off an activist challenge to its $74 billion takeover of cancer specialist Celgene earlier this month.
Global stocks pared gains Thursday, as weakening data and dovish central bank actions added to concerns over the pace of world growth and offset the bullish tenor from last night's after-the-bell earnings on Wall Street.
Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb) announced today the commencement, in connection with its previously announced acquisition of Celgene Corporation (NASDAQ:CELG) ("Celgene") , of an exchange offer for any and all outstanding...
Jim Cramer says this positive start will be hard to sustain this earnings season. He's got your game plan for next week.
Three quarters of Bristol-Myers Squibb shareholders vote to approve the deal with Celgene, paving the way for the largest pharmaceutical takeover in history.
Celgene Corporation (NASDAQ: CELG) today announced that its stockholders have voted to approve the company's proposed combination with Bristol-Myers Squibb Company (NYSE: BMY).
Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that Celgene has submitted a Biologics License Application (BLA) for luspatercept, an erythroid maturation agent, for the treatment of adult patients with very low...
How can stocks rally with money coming out so swiftly? Jim Cramer says to take a look at the 5 best performing stocks in the Dow for the first quarter.
Jim Cramer takes a look at Williams-Sonoma, Fortive, Western Digital, Goodyear Tire & Rubber, Celgene, Welltower, Box and Twitter.
The myriad names in oncology have been the hottest area for acquisitions along with gene therapy.
Celgene surges Friday after an influential shareholder advisory group recommend investors vote in favor of the cancer drug specialist's takeover by Bristol-Myers Squibb Co. while a key activist dropped its opposition to the $74 billion deal.
Celgene Corporation (NASDAQ:CELG) and Lotus Pharmaceutical Co., Ltd.
Celgene Corporation (NASDAQ:CELG), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinions for two triplet regimens based on Celgene's proprietary IMiD ® medications,...
Lots of IPOs and innovation will reward investors who do their homework, Jim Cramer says.
The biotech sector isn't for the faint of heart, but these two companies issued promising news this week.
Bristol-Myers Squibb says Tuesday the Federal Trade Commission has requested information related to its planned $74 billion takeover of cancer drug company Celgene.
Jim Cramer takes a look at Bristol-Myers Squibb, Xilinx, Nieslen, Realty Income, W&T Offshore and more.
Celgene Corporation (NASDAQ:CELG) today announced that the Company has submitted a New Drug Application to the U.
Bristol-Myers Squibb Company's (NYSE:BMY) Board of Directors today sent an open letter to the Company's shareholders regarding the previously announced definitive merger agreement with Celgene Corporation (NASDAQ:CELG).
Bristol-Myers Squibb trades blows with activist investor Starboard Value Tuesday as the pair issues competing presentations linked to the pharmaceutical group's planned $74 billion takeover of cancer drug specialist Celgene.
Jim Cramer thinks that Bristol-Myer's deal with Celgene is a positive thing, despite Starboard's resistance.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.